Arecor's Insulin Candidate Achieves Positive Results in Phase 1 Trial
September 20 2021 - 2:31AM
Dow Jones News
By Anthony O. Goriainoff
Arecor Therapeutics PLC said Monday that its insulin candidate
for diabetes, AT278, met all primary and secondary endpoints with
positive headline results from the Phase 1 clinical trial.
The London-listed biopharmaceutical company--backed by Unilever
PLC--said AT278 had the potential to significantly improve post
prandial glucose control and reduce the injection volume and/or
number of daily injections of people with diabetes who have a high
daily insulin need.
"These positive data for AT278, the second product in our
diabetes franchise, follow the earlier positive results from the
Phase I clinical trial of AT247... Together they position Arecor
with a unique combination of ultra-concentrated and ultra-rapid
insulin candidates offering the potential to meet the broad needs
of patients across the growing diabetes market," Chief Executive
Sarah Howell said.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 20, 2021 03:16 ET (07:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Unilever (NYSE:UL)
Historical Stock Chart
From Apr 2024 to May 2024
Unilever (NYSE:UL)
Historical Stock Chart
From May 2023 to May 2024